They say a picture’s worth a thousand words, and Sanofi and Regeneron are using that exchange rate to their advantage with Libtayo. The teammates have FDA approval to show before-and-after ...

Despite innovative pipeline assets, Regeneron's stock recovery above $1,000 is unlikely due to Eylea's revenue decline and lack of blockbuster drugs. The Pharma is fairly priced today, in my view.

while REGN records its share of profits/losses in connection with global sales of the drug. Regeneron is also looking to foray into the challenging but promising nonalcoholic steatohepatitis (NASH ...

(Reuters) - Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France ...

The synthetic DNA weaver Twist Bioscience has teamed up with Regeneron to deliver a custom next-generation sequencing test that can track minute genetic differences among global populations.

Morningstar brands and products Company Portfolio ...

The deal is also expected to create approximately 1,000 full-time, high-skill jobs. 1 “Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honor for us, as ...

Okay, great. Good morning and welcome to Day 2 of the Barclays Global Healthcare Conference. I am Carter Gould, Senior Biopharma Analyst here. I am pleased to welcome Regeneron to the next session ...

The outlook is stable. Ratings assigned: Issuer rating, Baa3 Outlook Actions: Outlook assigned stable "Regeneron's investment grade rating reflects growing global scale, strong scientific ...